Is Zogenix publicly traded?
Zogenix, Inc.’s stock symbol is ZGNX and currently trades under NASDAQ.
Is Zogenix a good investment?
Zogenix has received a consensus rating of Hold. The company’s average rating score is 2.22, and is based on 2 buy ratings, 7 hold ratings, and no sell ratings.
What happened to Zogenix?
Pursuant to the terms of the merger agreement, Purchaser merged with and into Zogenix on 7 March 2022. As a result of the merger, Zogenix has become a wholly-owned subsidiary of UCB and the common stock of Zogenix will be delisted from the NASDAQ Global Market.
What is Zogenix used for?
Complementing UCB’s existing therapeutic offerings, the Zogenix acquisition provides UCB with an approved medicine for a life-threatening, rare infant- and childhood-onset epilepsy marked by frequent and severe treatment-resistant seizures, that are particularly challenging to treat,” said Charl van Zyl , Executive …
Is Zogenix a good company?
Excellent Company Great company culture and management. Great benefits and a great product that is successful. Not much room for advancement unless you are in management.
What type of company is Zogenix?
specialty pharmaceutical company
Zogenix Inc (Zogenix) is a specialty pharmaceutical company that develops and markets therapies for the treatment of patients with rare diseases. The company’s marketed products include Fintepla (fenfluramine) approved in the US, the UK and EU for the treatment of seizures associated with the Dravet syndrome.
Where is zogenix located?
Zogenix is headquartered in Emeryville, California, the US.
How many employees does zogenix have?
Based in California, Zogenix is a small pharmaceutical company with only 90 employees and an annual revenue of $13.6M.
What is Zogenix stock symbol?
ZGNX
Zogenix Inc (ZGNX)
Is fenfluramine still available?
Fenfluramine was withdrawn from the U.S. market in 1997 after reports of heart valve disease and continued findings of pulmonary hypertension, including a condition known as cardiac fibrosis.